KIR3DL1 and leukemia: The tumor burden was significantly reduced by ADAPT-NK cell transfer for the duration of the experiment, with substantially better leukemia control by HLA-C/KIR mismatched ADAPT-NK cells by day 35 (figure 4D, E).